Biotech Charts II (fka )

[surf1944]

8:33AM Immunomedics reports first experimental studies combining antibody-drug conjugate with antibody-directed radiation therapy for pancreatic cancer (IMMU) 3.53 : Co announced that combining antibody-directed drug and radionuclide therapeutics for pancreatic cancer improved efficacy in preclinical studies with minimal toxicity. Results from these investigations were presented at the 2011 Gastrointestinal Cancers Symposium. Two of the Company's proprietary humanized antibodies were involved in this research. Clivatuzumab, which selectively targets pancreatic cancer, has shown in preclinical and early clinical studies promising therapeutic activity when labeled with yttrium-90 (Y-90) and in combination with gemcitabine. hRS7 has been shown to internalize into cancer cells when bound to its receptor, EGP-1, or TROP-2, making it an attractive antibody for delivery of cytotoxic drugs.